Biotechnology company ZandCell LLC reported on Tuesday the availability of a fast, reliable and affordable COVID-19 saliva based rapid antigen test kit to be used in airports, governments, states, hospitals, sports events and for healthcare workers.
According to ZandCell, its COVID-19 Rapid Antigen Test rapidly tests to qualitatively detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
The saliva-based ZandCell COVID-19 Rapid Antigen Test is now available in large quantities and can quickly and effectively test patients for the infectious virus and provide immediate results within three to ten minutes.
ZandCell COVID-19 Rapid Antigen Test was CE certified on 11 September and will be available in the US upon EUA FDA approval.
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance
Vascarta commences NIH phase I clinical study of VAS-101 in sickle cell disease
Azra AI and 4DMedical partner on lung health intelligence
AstraZeneca reports positive Phase III results for Tagrisso and Orpathys
HUTCHMED reports positive Phase III results for ORPATHYS and TAGRISSO combination
ArkBio's Ziresovir gains US FDA Phase II clinical trial approval
Pharming launches Joenja in Japan for APDS patients aged four and above
Galvanize Therapeutics' new Aliya EX System completes first commercial procedures
Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas